Prosecution Insights
Last updated: November 08, 2026
Application No. 18/434,530

Biological Patch and Fixation Device for Tendon Repair

Non-Final OA §103
Filed
Feb 06, 2024
Priority
Feb 07, 2023 — provisional 63/483,703
Examiner
ALEMAN, SARAH WEBB
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Kirigenx Inc.
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
10m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
375 granted / 602 resolved
-7.7% vs TC avg
Strong +24% interview lift
Without
With
+23.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
33 currently pending
Career history
640
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
49.6%
+9.6% vs TC avg
§102
21.4%
-18.6% vs TC avg
§112
19.9%
-20.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 602 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Claim 11 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 9/15/2026. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1, 4, 5, 7, 8 and 10 are rejected under 35 U.S.C. 103 as being unpatentable over USPAP 2022/0338910 (Kucklick) in view of US 6,007,567 (Bonutti). Regarding claim 1, Kucklick discloses a regenerative patch system for treating a tendon comprising a rollable scaffold (62) (see rolled configuration in Figure 3) comprising a first sheet (64) and a second sheet (65) opposing the first sheet (see Figures 23A-C), the second sheet (51) having a first surface and a second surface wherein the first surface includes microchannels (68) to flow fluid through the second surface and wherein the first sheet and the second sheet enclose the microchannels between the two sheets [0051]. Kucklick discloses the scaffold is attached to tissue with sutures, staples, etc. [0050; 0053], but fails to disclose details of a fastener having fluid channels and a suture securing the fastener to the rollable scaffold. Bonutti discloses a suture (38) and anchor (20) combination for attaching to a tendon and/or an implant (col 7, lines 46-54), wherein the suture anchor (20) comprises a porous structure defining fluid channels that allows the material to absorb body liquid (abstract). The anchor expands as it absorbs fluid and improves the interlock with the surrounding tissue to withstand greater forces applied to the suture (col 2, lines 42-60; col 7, lines 46-54). One of ordinary skill in the art before the effective filing date of the claimed invention would have found it obvious to combine the suture and suture anchor taught by Bonutti with the Kucklick scaffold, as the modification combines a known fastening structure to obtain a predictable result of securing an implantable scaffold to a patient’s tissue. The language “the patch system adapted to flow fluid from the fastener via the suture, to the patch” is a functional recitation that is not given full patentable weight. The prior art is not required to explicitly disclose fluid flow but merely have the capability of performing the function. Kucklick discloses the microchannels of the sheet allow fluid flow through apertures (69) [0051; 0053] and Bonutti discloses that body fluid flows through the suture anchor. The suture, anchor and scaffold are coupled together such that surrounding body fluid is capable of flowing from the fastener via the suture to the patch. In regard to claim 4, a suture monofilament suture is well known in the art. Regarding claim 5, the phrase “scaffold is formed by electrospinning” is a product-by-process limitation that is not given patentable weight, as the method by which the product is made is not germane to the issue of patentability of the device itself. In regard to claim 7 and 8, the fastener taught by Bonutti can be described as a tack or staple, since the claims do not specify any particular structural features. In regard to claim 10, the second surface of the second sheet (65) further includes a reservoir capable of functioning to collect fluid (wherein a portion of frame 67 or inner members 68 defining channels can be considered a reservoir while another portion meets the requirement of microchannels of claim 1 [0051]). Claim(s) 2, 3, 6 and 9 are rejected under 35 U.S.C. 103 as being unpatentable over Kucklick in view of Bonutti, as applied to claim 1 above, and further in view of USPAP 2011/0087271 (Sargeant et al.). Regarding claims 3 and 6, Kucklick states the scaffold may be made of bio-reabsorbable materials [0052] but fails to disclose specific materials of construction of the scaffold. Sargeant discloses another surgical patch and teaches that a suitable biodegradable material is poly(1-lactide-co-ε-caprolactone) [0038]. Since Sargeant is in the same field of endeavor of a surgical scaffold in the form of a sheet for wound repair, one of ordinary skill in the art before the effective filing date of the claimed invention would have found it obvious to form the second sheet to comprise poly(1-lactide-co-ε-caprolactone), as the modification merely involves a combination of known biodegradable materials that achieves a predictable result of a surgical mesh with biodegradable properties. Additionally, it has been held to be within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended use as a matter of obvious design choice. In re Leshin, 125 USPQ 416. Regarding claims 2 and 9, Sargeant further teaches that it is known in the art for the surgical mesh to comprise collagen, hydrogel and/or hyaluronic acid [0053; 0041] to aid in the regeneration of tissue [0054]. One of ordinary skill in the art before the effective filing date of the claimed invention would have found it obvious to form the modified Kucklick scaffold to comprise collagen, and/or hydrogel or hyaluronic acid, as taught by Sargeant, in order to promote regeneration of tissue and to achieve the desired therapeutic effect. Additionally, it has been held to be within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended use as a matter of obvious design choice. In re Leshin, 125 USPQ 416. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. USPAP 2015/0250576 (Blackburn) discloses a rollable, multilayered surgical scaffold. USPAP 2014/0277133 and USPAP 2015/0173739 disclose suture anchors with a plurality of channels. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH WEBB ALEMAN whose telephone number is (571)272-5749. The examiner can normally be reached M, Tu, Th, Fr 9am - 3pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melanie Tyson can be reached at 571-272-9062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SARAH W ALEMAN/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Feb 06, 2024
Application Filed
Sep 25, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766000
HEART VALVE REPAIR
4y 8m to grant Granted Oct 20, 2026
Patent 12751710
DEVICES AND METHODS FOR OCCLUDING OR PROMOTING FLUID FLOW
3y 5m to grant Granted Oct 06, 2026
Patent 12740880
DEVICES AND METHODS FOR TREATING BRANCHING BLOOD VESSELS
4y 0m to grant Granted Sep 22, 2026
Patent 12734056
MEDICAL TUBULAR BODY DELIVERING DEVICE
4y 3m to grant Granted Sep 15, 2026
Patent 12714586
BIFURCATED BALLOON EXPANDABLE STENT ASSEMBLY
4y 1m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
86%
With Interview (+23.7%)
3y 7m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 602 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month